July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Clinical Outcomes for Intravenous Immunoglobulin Treatment in Autoimmune Retinopathy with Comparison to Natural History Controls
Author Affiliations & Notes
  • Caroline Minkus
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Lucia Sobrin
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Lynn Stanwyck
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Caroline Minkus, None; Lucia Sobrin, None; Lynn Stanwyck, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3501. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Caroline Minkus, Lucia Sobrin, Lynn Stanwyck; Clinical Outcomes for Intravenous Immunoglobulin Treatment in Autoimmune Retinopathy with Comparison to Natural History Controls. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3501.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this study was to compare clinical outcomes between autoimmune retinopathy (AIR) patients treated with intravenous immunoglobulin (IVIg) and AIR patients who did not receive any treatment.

Methods : We retrospectively reviewed the charts of patients diagnosed with AIR at Massachusetts Eye and Ear from 1988 to 2018.We identified patients who were either not treated or who were treated with IVIg. Clinical measures including visual acuity (VA), electroretinogram (ERG) parameters, and visual field (VF) area were recorded. For the natural history patients, these measures were analyzed at their first visit and last visits. For those patients treated with IVIg, the measures were analyzed at their last visit prior to starting IVIg and their most recent visit while receiving IVIg. The ttest was used to compare the mean change in VA between the two groups. Statistical tests were executed in STATA 12.1.

Results : Ten patients with untreated AIR (4 men, 6 women, mean age = 55.8 years) and eight AIR patients treated with IVIg (5 men, 3 women, mean age = 56.3 years) were identified. Natural history patients’ VA declined at an average rate of 0.009 logMAR/month, while those treated with IVIg showed an average improvement of 0.012 logMAR/month. However, this difference was not statistically significant (P=0.26). Of patients with longitudinal ERG data, four (40%) of the natural history patients showed worsening of their ERG while six (60%) remained stable; four IVIg-treated (67%) patients remained stable, and two (33%) worsened. Of patients with longitudinal VF data, six (75%) natural history patients’ VF worsened, one (12.5%) improved, and one (12.5%) remained stable; one (25%) IVIg-treated patient worsened on VF, two (50%) improved, and one (25%) remained stable.

Conclusions : Patients with untreated AIR had, on average, a gradual decline in VA, as well as stability or worsening of their VF and ERG. By comparison, patients treated with IVIg had, on average, a gradual improvement in VA, and were less likely to show a decline on ERG, and more likely to show an improvement on VF. This study is limited by its small sample size; however, it provides insight into the natural history and clinical course of AIR, and suggests that IVIg may be an effective therapy that warrants further investigation in a larger number of patients.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×